Skip to main content
BFRI
NASDAQ Life Sciences

Biofrontera Inc. Announces Record Preliminary Q4 2025 Revenues, Exceeding $17M with Strong YOY Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.785
Mkt Cap
$9.354M
52W Low
$0.536
52W High
$1.24
52W Position info
46% above low
Off High info
37% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

BFRI sits 46% above its 52-week low of $0.536 on elevated volume (2.2× avg).

Summary

Biofrontera Inc. announced preliminary record revenues for the fourth quarter of 2025, ranging from $17.0 million to $17.5 million, alongside strong double-digit full-year growth.


Key Events · Earnings and Guidance · BFRI

  • Record Quarterly Revenue

    Preliminary unaudited revenues for Q4 2025 are projected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the company's history.

  • Strong Year-Over-Year Growth

    The Q4 2025 revenue figures reflect approximately 35% to 39% year-over-year growth, primarily driven by sales execution of Ameluz®.

  • Positive Full-Year Performance

    Full year 2025 revenues are expected to be in the range of $41.5 million to $42.0 million, indicating double-digit growth of 11% to 13% year-over-year.

  • Strategic Foundation Strengthened

    Management noted that a recent transformational transaction with Biofrontera AG is expected to meaningfully improve the gross margin profile and strengthen the financial foundation.


Analysis · BFRI · Life Sciences

Biofrontera Inc. reported preliminary unaudited revenues for Q4 2025 between $17.0 million and $17.5 million, marking the highest quarterly revenue in the company's history. This represents significant year-over-year growth of approximately 35% to 39%. For a company with a market capitalization of under $10 million, these revenue figures are exceptionally strong and indicate robust operational performance. The CEO highlighted strong execution, continued growth of Ameluz® PDT, and a recent transformational transaction with Biofrontera AG that is expected to improve gross margin and strengthen the financial foundation. This positive update could significantly re-rate the company's valuation and investment thesis.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BFRI was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.54 to $1.24. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BFRI - Latest Insights

BFRI
Nov 20, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.530
Real-time Price: $0.5401 info
Change: +$0.0101 (+2%) info
Market Cap: $9.513M info
BFRI
Nov 13, 2026, 4:46 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.700
Real-time Price: $0.5401 info
Change: -$0.1599 (-23%) info
Market Cap: $9.513M info
BFRI
Nov 13, 2026, 8:03 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.813
Real-time Price: $0.5401 info
Change: -$0.2729 (-34%) info
Market Cap: $9.513M info
BFRI
Oct 08, 2026, 9:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.9722
Real-time Price: $0.5401 info
Change: -$0.4321 (-44%) info
Market Cap: $9.513M info
BFRI
Sep 14, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.55
Real-time Price: $0.5401 info
Change: -$1.01 (-65%) info
Market Cap: $9.513M info